212 related articles for article (PubMed ID: 30892035)
1. Tumor-Targeted Delivery of 6-Diazo-5-oxo-l-norleucine (DON) Using Substituted Acetylated Lysine Prodrugs.
Tenora L; Alt J; Dash RP; Gadiano AJ; Novotná K; Veeravalli V; Lam J; Kirkpatrick QR; Lemberg KM; Majer P; Rais R; Slusher BS
J Med Chem; 2019 Apr; 62(7):3524-3538. PubMed ID: 30892035
[TBL] [Abstract][Full Text] [Related]
2. Discovery of
Novotná K; Tenora L; Prchalová E; Paule J; Alt J; Veeravalli V; Lam J; Wu Y; Šnajdr I; Gori S; Mettu VS; Tsukamoto T; Majer P; Slusher BS; Rais R
J Med Chem; 2023 Nov; 66(22):15493-15510. PubMed ID: 37949450
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 6-Diazo-5-oxo-l-norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma.
Rais R; Jančařík A; Tenora L; Nedelcovych M; Alt J; Englert J; Rojas C; Le A; Elgogary A; Tan J; Monincová L; Pate K; Adams R; Ferraris D; Powell J; Majer P; Slusher BS
J Med Chem; 2016 Sep; 59(18):8621-33. PubMed ID: 27560860
[TBL] [Abstract][Full Text] [Related]
4. Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug.
Rais R; Lemberg KM; Tenora L; Arwood ML; Pal A; Alt J; Wu Y; Lam J; Aguilar JMH; Zhao L; Peters DE; Tallon C; Pandey R; Thomas AG; Dash RP; Seiwert T; Majer P; Leone RD; Powell JD; Slusher BS
Sci Adv; 2022 Nov; 8(46):eabq5925. PubMed ID: 36383674
[TBL] [Abstract][Full Text] [Related]
5. We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of
Lemberg KM; Vornov JJ; Rais R; Slusher BS
Mol Cancer Ther; 2018 Sep; 17(9):1824-1832. PubMed ID: 30181331
[TBL] [Abstract][Full Text] [Related]
6. N-(Pivaloyloxy)alkoxy-carbonyl Prodrugs of the Glutamine Antagonist 6-Diazo-5-oxo-l-norleucine (DON) as a Potential Treatment for HIV Associated Neurocognitive Disorders.
Nedelcovych MT; Tenora L; Kim BH; Kelschenbach J; Chao W; Hadas E; Jančařík A; Prchalová E; Zimmermann SC; Dash RP; Gadiano AJ; Garrett C; Furtmüller G; Oh B; Brandacher G; Alt J; Majer P; Volsky DJ; Rais R; Slusher BS
J Med Chem; 2017 Aug; 60(16):7186-7198. PubMed ID: 28759224
[TBL] [Abstract][Full Text] [Related]
7. Model studies towards prodrugs of the glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON) containing a diazo precursor.
Gao RD; Hin N; Prchalová E; Pal A; Lam J; Rais R; Slusher BS; Tsukamoto T
Bioorg Med Chem Lett; 2021 Oct; 50():128321. PubMed ID: 34400301
[TBL] [Abstract][Full Text] [Related]
8. Novel Glutamine Antagonist JHU395 Suppresses MYC-Driven Medulloblastoma Growth and Induces Apoptosis.
Pham K; Maxwell MJ; Sweeney H; Alt J; Rais R; Eberhart CG; Slusher BS; Raabe EH
J Neuropathol Exp Neurol; 2021 Mar; 80(4):336-344. PubMed ID: 33712838
[TBL] [Abstract][Full Text] [Related]
9. L-asparaginase and 6-diazo-5-oxo-L-norleucine synergistically inhibit the growth of glioblastoma cells.
Ohba S; Hirose Y
J Neurooncol; 2020 Feb; 146(3):469-475. PubMed ID: 32020477
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children.
Sullivan MP; Nelson JA; Feldman S; Van Nguyen B
Cancer Chemother Pharmacol; 1988; 21(1):78-84. PubMed ID: 3342470
[TBL] [Abstract][Full Text] [Related]
11. A redox-responsive prodrug for tumor-targeted glutamine restriction.
Prange CJ; Sayed NYB; Feng B; Goepfert C; Trujillo DO; Hu X; Tang L
J Control Release; 2024 Apr; 368():251-264. PubMed ID: 38403173
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-activated glutamine antagonist prodrug combined with combretastatin A4 nanoparticles for tumor-selective metabolic blockade.
Zheng M; Xu H; Huang Y; Sun J; Zhang H; Lv Z; Liu Z; Tang Z; Chen X
J Control Release; 2024 Jan; 365():480-490. PubMed ID: 38040341
[TBL] [Abstract][Full Text] [Related]
13. Bioanalysis of 6-diazo-5-oxo-l-norleucine in plasma and brain by ultra-performance liquid chromatography mass spectrometry.
Alt J; Potter MC; Rojas C; Slusher BS
Anal Biochem; 2015 Apr; 474():28-34. PubMed ID: 25584882
[TBL] [Abstract][Full Text] [Related]
14. Phase I study and clinical pharmacology of 6-diazo-5-oxo-L-norleucine (DON).
Rahman A; Smith FP; Luc PT; Woolley PV
Invest New Drugs; 1985; 3(4):369-74. PubMed ID: 4086244
[TBL] [Abstract][Full Text] [Related]
15. Antagonizing Bcl-2 family members sensitizes neuroblastoma and Ewing's sarcoma to an inhibitor of glutamine metabolism.
Olsen RR; Mary-Sinclair MN; Yin Z; Freeman KW
PLoS One; 2015; 10(1):e0116998. PubMed ID: 25615615
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of genetic toxicity of 6-diazo-5-oxo-l-norleucine (DON).
Kulkarni RM; Dakoulas EW; Miller KE; Terse PS
Toxicol Mech Methods; 2017 Sep; 27(7):518-527. PubMed ID: 28552037
[TBL] [Abstract][Full Text] [Related]
17. Uptake of glutamine antimetabolites 6-diazo-5-oxo-L-norleucine (DON) and acivicin in sensitive and resistant tumor cell lines.
Huber KR; Rosenfeld H; Roberts J
Int J Cancer; 1988 May; 41(5):752-5. PubMed ID: 3366493
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of 6-diazo-5-oxo-L-norleucine (DON).
Sklaroff RB; Casper ES; Magill GB; Young CW
Cancer Treat Rep; 1980; 64(12):1247-51. PubMed ID: 7471114
[TBL] [Abstract][Full Text] [Related]
19. Influence of 6-diazo-5-oxo-L-norleucine (DON), a glutamine analogue, on cartilaginous differentiation in mouse limb buds in vitro.
Aydelotte MB; Kochhar DM
Differentiation; 1975 Oct; 4(2):73-80. PubMed ID: 1183764
[TBL] [Abstract][Full Text] [Related]
20. Phase II evaluation of DON (6-diazo-5-oxo-L-norleucine) in patients with advanced colorectal carcinoma.
Lynch G; Kemeny N; Casper E
Am J Clin Oncol; 1982 Oct; 5(5):541-3. PubMed ID: 7180833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]